Cinacalcet Tablet, Film Coated
Product Images NDC 67877-505

7 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 67877-505). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cinacalcet-figure-1.jpg (Cinacalcet Figure 1)

Cinacalcet-figure-1.jpg (Cinacalcet Figure 1)
A line graph depicting mean intact parathyroid hormone (iPTH) levels (pg/mL) over 26 weeks from pooled phase 3 studies. Two curves compare the effects of Cinacalcet versus placebo, showing iPTH values decreasing steadily with Cinacalcet treatment, while placebo values remain relatively stable.*
FDA Label Image

Cinacalcet-figure-2 (Cinacalcet Figure 2)

Cinacalcet-figure-2 (Cinacalcet Figure 2)
A line graph titled 'Figure 2. Mean (SE) Ca x P Values (Pooled Phase 3 Studies)' comparing calcium-phosphorus product levels (mg/dL) over 26 weeks between placebo and Cinacalcet groups. The x-axis shows weeks (0 to 26), and the y-axis shows Ca x P values from 0 to 70. The Cinacalcet group shows a decrease in values over time, while the placebo group remains relatively stable.*
FDA Label Image

Cinacalcet-fig3 (Cinacalcet Fig3)

Cinacalcet-fig3 (Cinacalcet Fig3)
A line graph depicting calcium levels (mg/dL) over time in weeks during titration and maintenance phases for patients with parathyroid carcinoma. The X-axis represents weeks from baseline through 80 weeks, and the Y-axis shows calcium concentration ranging from 8 to 16 mg/dL. Data points include error bars indicating variability.*
FDA Label Image

Cinacalcet-fig4.jpg (Cinacalcet Fig4)

Cinacalcet-fig4.jpg (Cinacalcet Fig4)
A line graph showing serum calcium levels (mg/dL) over time (weeks) during titration and maintenance phases for a treatment, with calcium levels generally decreasing and stabilizing after titration. The x-axis represents weeks, and the y-axis shows calcium concentration, including the number of subjects with intractable pHPT at each time point.*
FDA Label Image

Cinacalcet Tablets 30 mg 30 Tablets (Cina 30mg 30 Tab 1)

Cinacalcet Tablets 30 mg 30 Tablets (Cina 30mg 30 Tab 1)
Packaging label for Cinacalcet Tablets 30 mg film-coated oral tablets by Ascend Laboratories, LLC. The label includes NDC 67877-503-30 and indicates a package size of 30 tablets. It specifies prescription use, storage instructions, manufacturers, and distributors, with a purple dosage strength box.*
FDA Label Image

Cinacalcet Tablets 60 mg 30 Tablets (Cina 60mg 30 Tab 2)

Cinacalcet Tablets 60 mg 30 Tablets (Cina 60mg 30 Tab 2)
Cinacalcet Tablets 60 mg film-coated oral tablets label by Ascend Laboratories, LLC. The label includes dosage strength 60 mg, quantity of 30 tablets, and manufacturer information from Alkem Laboratories, Ltd., India, distributed by Ascend Laboratories, NJ. Storage instructions and dosage dispensing notes are also visible along with barcodes and NDC number 67877-504-30.*
FDA Label Image

Cinacalcet Tablets 90 mg 30 Tablets (Cina 90mg 30 Tab 3)

Cinacalcet Tablets 90 mg 30 Tablets (Cina 90mg 30 Tab 3)
Label for Cinacalcet Tablets 90 mg, film-coated oral tablets. The label shows the strength (90 mg) prominently, with a package count of 30 tablets. It is labeled for prescription use only (Rx Only). The labeler is Ascend Laboratories, LLC, and the NDC is 67877-505-30. Storage instructions, manufacturer information, and a barcode are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.